GT方案治疗老年晚期非小细胞肺癌的临床疗效观察

Efficacy of GT Regimen in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

目的观察GT方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法 60例老年晚期老年晚期NSCLC患者接受化疗:吉西他滨1 000 mg·m^(-2),静脉滴注,d_(1,8);多西他赛60 mg·m^(-2),静脉滴注,d1,每21 d为1周期,至少应用2周期后评价疗效。结果 60例患者中,CR 5例,PR 14例,SD 17例,PD 24例,总有效率为31.7%(19/60),初治组有效率为37.8%(14/37),复治组有效率为26.1%(6/23);腺癌有效率为36.7%,鳞癌有效率为36.3%;初治与复治、不同的病理类型间有效率比较差异均无统计学意义(P>0.05)。主要毒副反应为骨髓抑制。结论 GT方案在老年晚期NSCLC患者的应用中安全有效,值得进一步研究。

Objective To observe the clinical efficacy and toxicities of GT regimen in the treatment of elderly patients with non-small cell lung cancer （NSCLC）. Methods Sixty elderly patients with NSCLC were treated by gemcitabine and docetaxel, and then the efficacy was evaluated after at least two cycles. Results In the 60 patients, CR 5 patients, PR 14 patients, SD 17 patients and PD 24 patients. The totally effective rate was 31.7% （19/60） while the effective rate of the newly diagnosed patients was 37.8% （14/37） and the relapsed patients was 26.1% （6/23）. The effective rate of the adenocarcinoma and the squamous cell carcinoma was 36.7% and 36.3% （P 〉 0. 05）. The main toxicity was bone marrow suppression. Conclusion GT regimen is effective and safe in the treatment of elderly patients with NSCLC.